Clinical evidence on the use of anti-mTOR drugs in renal transplantation;Evidencias clínicas sobre el uso de los fármacos anti-mTOR en el trasplante renal

Nefrologia

Volumn 31, Issue 1, 2011, Pages 27-34

  Marrero, Domingo Hernández ^a   Martinez D ^a   Gutierrez E ^a   Lopez V ^a   Gutierrez C ^a   Garcia P ^a   Cobelo, C ^a   Cabello, M ^a   Burgos, D ^a   Sola, E ^a   Gonzalez Molina M ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Anti mTOR drugs; Everolimus; Proliferation signal inhibitors; Renal transplantation; Sirolimus

Indexed keywords

CALCINEURIN; DRUG DERIVATIVE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL; ANIMAL MODEL; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG ANTAGONISM; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; CALCINEURIN; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MODELS, ANIMAL; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79751504331     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Jul.10512     Document Type: Review

References (73)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378-83.
2. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20:2493-502.
3. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-42.
4. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60.
5. Tran HT, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H, et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000;11:1903-9.
6. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2000;71:1282-7.
7. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070-6.
8. Grinyo JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003;16:820-7.
9. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and caloriginales inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004;77:1228-35.
10. Hernández D, González-Posada JM. Evidencias en la inmunosupresión de mantenimiento en el trasplante renal. Nefrologia 2005;25:369-80.
11. Pascual J. Everolimus: immunosuppression with antilymphoproliferative therapy. Nefrologia 2004;24:112-23.
12. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004;4:1776-85.
13. Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing I, Rifle G, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010;89:1511-7.
14. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12.
15. Morelon E, Lefrançois N, Besson C, Prévautel J, Brunet M, Touraine JL, et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol 2010;23:53-8.
16. Pascual J. Everolimus in clinical practice renal transplantation. Nephrol Dial Transplant 2006;21(Suppl 3):iii18-23.
17. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52.
18. Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-30.
19. Tedesco-Silva H Jr, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007;20:27-36.
20. Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009;88:1194-202.
21. Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010;10:1401-13.
22. Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010 May 24 [Epub ahead of print].
23. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008;85:821-6.
24. Pascual J, Del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernáncasdez AM, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation 2010;89:994-1000.
25. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75.
26. Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009;88:69-76.
27. Hernández D, Rufino M, Armas S, González A, Gutiérrez P, Barbero P, et al. Retrospective analysis of surgical complications following cadaveric kidney transplantation in the modern transplant era. Nephrol Dial Transplant 2006;21:2908-15.
28. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155.
29. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005;5:1748-56.
30. Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, SMART-Study Group. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010; 90 :175-83.
31. Morales JM, Grinyó JM, Campistol JM, García-Martínez J, Arias M, Paul J, et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation 2008;86:620-2.
32. Lee PC, Lee CY, Hu RH, Lo C, Tsai MK, Lee PH. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens. Nephrol Dial Transplant 2010;25:1675-80.
33. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42.
34. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009;9:1115-23.
35. Servais A, Meas-Yedid V, Toupance O, Lebranchu Y, Thierry A, Moulin B, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009;9:2552-60.
36. Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008;22:366-71.
37. Ruiz JC, Sánchez A, Rengel M, Beneyto I, Plaza JJ, Zárraga S, et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 2007;39:2157-9.
38. Fernández A, Marcén R, Galeano C, Caldés S, Amezquita Y, Villafruela J, et al. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. Transplant Proc 2009;41:2345-7.
39. Inza A, Balda S, Álvarez E, Zárraga S, Gaínza FJ, Lampreabe I. Conversion to everolimus in kidney transplant recipients with decreased renal function. Transplant Proc 2009;41:2134-6.
40. Bemelman FJ, De Maar EF, Press RR, Van Kan HJ, Ten Berge IJ, Homan van der Heide JJ, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009;88:421-8.
41. Sánchez-Fructuoso A, Ruiz JC, Hernández D, Sánchez-Plumed J, Fernández A, Pastor Rodríguez A, et al. Early everolimus introduction and calcineurine inhibitor withdrawal in renal transplant patients: a multicenter, randomized open-label study (The ERIC study) [abstract]. Am J Transplant 2010;10(Suppl. 4):506.
42. Lutz J, Zou H, Liu S, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003;76:508-15.
43. Koch M, Mengel M, Poehnert D, Nashan B. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 2007;83:498-50.
44. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004;4:953-61.
45. Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755-62.
46. Sola E, López V, Gutiérrez C, Cabello M, Burgos D, González Molina M, et al. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients. Transplant Proc 2009;41:2137-8.
47. Egli A, Köhli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation 2009;88:1161-8.
48. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007;84:83-8.
49. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010;5:335-43.
50. Van Ree RM, Oterdoom LH, de Vries AP, Homan van der Heide JJ, Van Son WJ, Navis G, et al. Circulating markers of endothelial dysfunction interact with proteinuria in predicting mortality in renal transplant recipients. Transplantation 2008;86:1713-9.
51. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004;109:3050-5.
52. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 2006;24:1663-70.
53. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009;75:800-8.
54. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008;52:324-30.
55. Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-42.
56. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003;3:562-9.
57. Ramzy D, Rao V, Tumiati LC, Xu N, Miriuka S, Delgado D, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006;114(1 Suppl):I214-9.
58. Joannides R, Etienne I, Iacob M, de Ligny BH, Barbier S, Bellien J, et al. Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int 2010 Jun 7. [Epub ahead of print].
59. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008;26:2213-9.
60. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234-48.
61. Fortun J, Martín-Dávila P, Pascual J, Cervera C, Moreno A, Gavaldá J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010 Jun 11. [Epub ahead of print].
62. Sun Y, Pei W, Welte T, Wu Y, Ye S, Yang Y. Cytomegalovirus infection is associated with elevated interleukin-10 in coronary artery disease. Atherosclerosis 2005;179:133-7.
63. De Mattos AM, Prather J, Olyaei AJ, Shibagaki Y, Keith DS, Mori M, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int 2006;70:757-64.
64. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35.
65. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236-44.
66. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19: 1411-8.
67. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57.
68. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
69. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20:2493-502.
70. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9.
71. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9.
72. Salgo R, Gossmann J, Schöfer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10:1385-93.
73. Barozzi P, Bonini C, Potenza L, Masetti M, Cappelli G, Gruarin P, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008;86:738-44.